Drug · DIN 00868965
SUPRAX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 14, 2017; first marketed December 31, 1990.
- Drug Identification Number (DIN)
- 00868965
- Company (DIN owner)
- Odan LaboratoriesltdPointe-Claire, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Suspension
- Route
- Oral
- Therapeutic class (ATC)
- Cefixime J01DD08
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CEFIXIME | 100 MG | 5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 14, 2017: NOC 19533New Drug Submission (NDS) · Transfer of drug identification numbers
- May 4, 2006: NOC 7927New Drug Submission (NDS) · Manufacturer name change
- December 24, 2004: NOC 6014New Drug Submission (NDS) · Manufacturer name change
Other DINs named SUPRAX
- DIN 00868981 · Marketed
- DIN 00868973 · Cancelled Post Market
- DIN 02195984 · Cancelled Post Market
- DIN 02195992 · Cancelled Post Market